Definium Therapeutics Inc
DFTXHealthcare|Biotechnology|USA
$47.07
-1.37 (-2.83%)
Tangible Book
$2.49
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06741228 A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) | Generalized Anxiety Disorder | P3 | Active | 214 | RCT, Double-blind | DT120 |
| NCT07592689 A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) | Major Depressive Disorder | P3 | Recruiting | 165 | RCT, Double-blind | DT120 |
| NCT06809595 A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | Generalized Anxiety Disorder | P3 | Active | 245 | RCT, Double-blind | DT120 |
| NCT06941844 A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge) | Major Depressive Disorder | P3 | Active | 149 | RCT, Double-blind | DT120 |
| NCT07303907 A Phase 2A Trial of DT402 for Autism Spectrum Disorder | Autism Spectrum Disorder, ASD | P2 | Recruiting | 20 | Open-label | DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) |
| NCT05200936 Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial | ADHD, Attention Deficit Disorder | P2 | Completed | 53 | RCT, Double-blind | MM120 |
| NCT05407064 A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms | Anxiety Generalized | P2 | Completed | 198 | RCT, Double-blind | MM120 |
| NCT04292197 A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers | Addiction | P1 | Completed | 108 | RCT, Double-blind | 18-MC Compound |
| NCT05753605 My Experiences: Leveraging Digital Technologies to Better Understand Mental Health | Mental Health Symptoms, Wearables | Completed | 302 | — | — |